Complement factor B mutation in atypical hemolytic uremic syndrome. Rare cause of rare disease

Luca Visconti, Valeria Cernaro, Gianluigi Ardissino, Martina Sgarbanti, Domenico Ferrara, Giuseppe Visconti, Domenico Santoro, Michele Buemi

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Hemolytic uremic syndrome (HUS) is a rare disease characterized by microangiopathic hemolysis, platelet consumption and multiple organ failure with predominant renal involvement. In the most of cases (85-90%), it is associated with enteric infection due to Shiga-toxin or verocytotoxin (STEC-VTEC)-producer Escherichia coli. Rarely, in about 10-15% of cases, HUS develops in the presence of a disorder of alternative complement pathway regulation and it is defined atypical (aHUS). We describe the case of a 65-year-old man who came to our attention with a clinical presentation of aHUS and a clinical course characterized by rapidly progressive acute renal failure (ARF), which required renal replacement treatments, and by a stable clinical picture of hematological impairment as a marker of a non-severe and self-limiting form. The clinical and laboratory course allowed us not to perform specific therapies such as plasma exchange and/or block of the complement with eculizumab. Less than two weeks after hospital admission, there was a gradual recovery of renal function with spontaneous diuresis and hematological remission. Genetic screening has revealed a heterozygous mutation in the complement factor B (CFB) that is not described in the literature and therefore not yet characterized in the genotype/phenotype correlation, also for the extreme rarity of the forms associated with CFB alteration. In conclusion, the presence of a new mutation in the CFB, such as the one described in our case, is probably associated with the development of aHUS but has not led to a poor prognosis, as generally reported in the literature for known variants of the CFB.

Original languageEnglish
Pages (from-to)74-81
Number of pages8
JournalGiornale italiano di nefrologia : organo ufficiale della Societa italiana di nefrologia
Volume34
Issue number2
Publication statusPublished - Apr 1 2017

Fingerprint

Complement Factor B
Rare Diseases
Shiga-Toxigenic Escherichia coli
Mutation
Hemolytic-Uremic Syndrome
Kidney
Shiga Toxin
Alternative Complement Pathway
Plasma Exchange
Multiple Organ Failure
Diuresis
Recovery of Function
Genetic Testing
Genetic Association Studies
Hemolysis
Acute Kidney Injury
Blood Platelets
Escherichia coli
Atypical Hemolytic Uremic Syndrome
Therapeutics

Keywords

  • Acute kidney injury
  • Atypical hemolytic uremic syndrome
  • Complement factor B mutations
  • Thrombotic microangiopathy

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Complement factor B mutation in atypical hemolytic uremic syndrome. Rare cause of rare disease. / Visconti, Luca; Cernaro, Valeria; Ardissino, Gianluigi; Sgarbanti, Martina; Ferrara, Domenico; Visconti, Giuseppe; Santoro, Domenico; Buemi, Michele.

In: Giornale italiano di nefrologia : organo ufficiale della Societa italiana di nefrologia, Vol. 34, No. 2, 01.04.2017, p. 74-81.

Research output: Contribution to journalArticle

Visconti, Luca ; Cernaro, Valeria ; Ardissino, Gianluigi ; Sgarbanti, Martina ; Ferrara, Domenico ; Visconti, Giuseppe ; Santoro, Domenico ; Buemi, Michele. / Complement factor B mutation in atypical hemolytic uremic syndrome. Rare cause of rare disease. In: Giornale italiano di nefrologia : organo ufficiale della Societa italiana di nefrologia. 2017 ; Vol. 34, No. 2. pp. 74-81.
@article{503c1d7abe3f40188b51f8dfa1ed00ac,
title = "Complement factor B mutation in atypical hemolytic uremic syndrome. Rare cause of rare disease",
abstract = "Hemolytic uremic syndrome (HUS) is a rare disease characterized by microangiopathic hemolysis, platelet consumption and multiple organ failure with predominant renal involvement. In the most of cases (85-90{\%}), it is associated with enteric infection due to Shiga-toxin or verocytotoxin (STEC-VTEC)-producer Escherichia coli. Rarely, in about 10-15{\%} of cases, HUS develops in the presence of a disorder of alternative complement pathway regulation and it is defined atypical (aHUS). We describe the case of a 65-year-old man who came to our attention with a clinical presentation of aHUS and a clinical course characterized by rapidly progressive acute renal failure (ARF), which required renal replacement treatments, and by a stable clinical picture of hematological impairment as a marker of a non-severe and self-limiting form. The clinical and laboratory course allowed us not to perform specific therapies such as plasma exchange and/or block of the complement with eculizumab. Less than two weeks after hospital admission, there was a gradual recovery of renal function with spontaneous diuresis and hematological remission. Genetic screening has revealed a heterozygous mutation in the complement factor B (CFB) that is not described in the literature and therefore not yet characterized in the genotype/phenotype correlation, also for the extreme rarity of the forms associated with CFB alteration. In conclusion, the presence of a new mutation in the CFB, such as the one described in our case, is probably associated with the development of aHUS but has not led to a poor prognosis, as generally reported in the literature for known variants of the CFB.",
keywords = "Acute kidney injury, Atypical hemolytic uremic syndrome, Complement factor B mutations, Thrombotic microangiopathy",
author = "Luca Visconti and Valeria Cernaro and Gianluigi Ardissino and Martina Sgarbanti and Domenico Ferrara and Giuseppe Visconti and Domenico Santoro and Michele Buemi",
year = "2017",
month = "4",
day = "1",
language = "English",
volume = "34",
pages = "74--81",
journal = "Giornale italiano di nefrologia : organo ufficiale della Società italiana di nefrologia",
issn = "0393-5590",
publisher = "Wichtig Publishing Srl",
number = "2",

}

TY - JOUR

T1 - Complement factor B mutation in atypical hemolytic uremic syndrome. Rare cause of rare disease

AU - Visconti, Luca

AU - Cernaro, Valeria

AU - Ardissino, Gianluigi

AU - Sgarbanti, Martina

AU - Ferrara, Domenico

AU - Visconti, Giuseppe

AU - Santoro, Domenico

AU - Buemi, Michele

PY - 2017/4/1

Y1 - 2017/4/1

N2 - Hemolytic uremic syndrome (HUS) is a rare disease characterized by microangiopathic hemolysis, platelet consumption and multiple organ failure with predominant renal involvement. In the most of cases (85-90%), it is associated with enteric infection due to Shiga-toxin or verocytotoxin (STEC-VTEC)-producer Escherichia coli. Rarely, in about 10-15% of cases, HUS develops in the presence of a disorder of alternative complement pathway regulation and it is defined atypical (aHUS). We describe the case of a 65-year-old man who came to our attention with a clinical presentation of aHUS and a clinical course characterized by rapidly progressive acute renal failure (ARF), which required renal replacement treatments, and by a stable clinical picture of hematological impairment as a marker of a non-severe and self-limiting form. The clinical and laboratory course allowed us not to perform specific therapies such as plasma exchange and/or block of the complement with eculizumab. Less than two weeks after hospital admission, there was a gradual recovery of renal function with spontaneous diuresis and hematological remission. Genetic screening has revealed a heterozygous mutation in the complement factor B (CFB) that is not described in the literature and therefore not yet characterized in the genotype/phenotype correlation, also for the extreme rarity of the forms associated with CFB alteration. In conclusion, the presence of a new mutation in the CFB, such as the one described in our case, is probably associated with the development of aHUS but has not led to a poor prognosis, as generally reported in the literature for known variants of the CFB.

AB - Hemolytic uremic syndrome (HUS) is a rare disease characterized by microangiopathic hemolysis, platelet consumption and multiple organ failure with predominant renal involvement. In the most of cases (85-90%), it is associated with enteric infection due to Shiga-toxin or verocytotoxin (STEC-VTEC)-producer Escherichia coli. Rarely, in about 10-15% of cases, HUS develops in the presence of a disorder of alternative complement pathway regulation and it is defined atypical (aHUS). We describe the case of a 65-year-old man who came to our attention with a clinical presentation of aHUS and a clinical course characterized by rapidly progressive acute renal failure (ARF), which required renal replacement treatments, and by a stable clinical picture of hematological impairment as a marker of a non-severe and self-limiting form. The clinical and laboratory course allowed us not to perform specific therapies such as plasma exchange and/or block of the complement with eculizumab. Less than two weeks after hospital admission, there was a gradual recovery of renal function with spontaneous diuresis and hematological remission. Genetic screening has revealed a heterozygous mutation in the complement factor B (CFB) that is not described in the literature and therefore not yet characterized in the genotype/phenotype correlation, also for the extreme rarity of the forms associated with CFB alteration. In conclusion, the presence of a new mutation in the CFB, such as the one described in our case, is probably associated with the development of aHUS but has not led to a poor prognosis, as generally reported in the literature for known variants of the CFB.

KW - Acute kidney injury

KW - Atypical hemolytic uremic syndrome

KW - Complement factor B mutations

KW - Thrombotic microangiopathy

UR - http://www.scopus.com/inward/record.url?scp=85032805471&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85032805471&partnerID=8YFLogxK

M3 - Article

C2 - 28682564

AN - SCOPUS:85032805471

VL - 34

SP - 74

EP - 81

JO - Giornale italiano di nefrologia : organo ufficiale della Società italiana di nefrologia

JF - Giornale italiano di nefrologia : organo ufficiale della Società italiana di nefrologia

SN - 0393-5590

IS - 2

ER -